Edward Lorenti Appointed as Instem VP Global Sales

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Instem, a leading provider of IT solutions to the global early development healthcare market, announced today it has named Edward Lorenti as its Vice President of Global Sales.

Lorenti has held a number of leadership positions within the Life Sciences industry and brings an extensive background in business and market development to Instem's management team.

Prior to joining Instem, Lorenti was sales director at Accenture (formerly Octagon Research Solutions, which they acquired in 2012) where he was responsible for their enterprise content management and submission software platform serving pharmaceutical and biotechnology organizations worldwide.

Lorenti's proven track record to build and manage high performing sales operations spans nearly 25 years and in this role will help Instem further shape, define and execute their strategic growth plans. Lorenti will be based out of Instem's US Headquarters but will be traveling extensively, and along with the experienced sales team he will be supporting current and prospective clients throughout North America, Europe and Asia-Pacific.

"We are delighted to bring Ed on board into this important role at this stage of our company's evolution," comments Phil Reason, CEO at Instem. "Ed has the comprehensive credentials to help us convert our dynamic product portfolio into software solutions that will further increase our growth across the R&D continuum. Our global sales team will certainly benefit from his day-to-day experience as a sales leader along with his demonstrated strategic abilities."

"I'm very excited about joining Instem – a great company with a seasoned, first class team – and look forward to the challenge of leading the global sales group to the next level of coverage and performance," comments Lorenti. "Listening to clients and staff will be a very high priority as we aim to increase market share in existing segments while opening up new areas with Instem's growing set of powerful technology solutions. Instem has built an excellent reputation for its innovation and client satisfaction, and I am very pleased to continue the efforts to deliver value to each and every user."

Instem has been developing, releasing and introducing a steady stream of technology solutions to the market in its mission to deliver data-driven insights. Capitalizing on its leadership within preclinical, Instem entered the early phase clinical market earlier this year (read news) with the ALPHADAS® EDC and automation software suite, a solution which organizations across four continents are using to accelerate and streamline clinical trial operations and service.

Instem plans to remain active in expanding the reach of its product portfolio into related scientific domains significantly reducing costs and cycle times while improving clients' quality of data. To learn more about Instem solutions and its mission, please visit www.instem.com.

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports its clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

http://www.linkedin.com/company/instem/

https://www.facebook.com/Instem.software

https://twitter.com/Instemsoftware

Meeting clients at the intersection of investment & return™.

Contacts

Instem
Gary Mitchell (US HQ)
Tel: 610-941-0990
[email protected]
or
Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600
[email protected]

 

Suggested Articles

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.

Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.

The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.